NCT03101748 2026-02-12
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
Clinical Trials
51 trialsNCT04578106 2026-01-06
ELPIS
Fundacio Clinic Barcelona
Phase 2 Terminated
NCT03501979 2025-08-29
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
University of Alabama at Birmingham
Phase 2 Terminated
NCT00520975 2025-03-28
Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
National Cancer Institute (NCI)
Phase 3 Terminated
NCT01897441 2024-12-24
Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer
Albert Einstein College of Medicine
Phase NA Terminated
NCT00963547 2024-06-04
MK-2206-015
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT01953926 2024-03-12
SUMMIT
Puma Biotechnology, Inc.
Phase 2 Terminated
NCT02771795 2024-02-02
A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC
Samsung Bioepis Co., Ltd.
Terminated
NCT03329378 2023-08-22
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT00272987 2023-04-28
ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
Novartis
Phase 3 Terminated
NCT04510285 2023-02-01
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT01779050 2022-11-01
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Washington University School of Medicine
Phase 2 Terminated
NCT05091528 2022-08-18
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
Silverback Therapeutics
Phase 1/2 Terminated
NCT02000596 2022-05-27
1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
University of Maryland, Baltimore
Phase 2 Terminated
NCT00810017 2022-05-19
Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer
Medstar Health Research Institute
Phase 2 Terminated
NCT02154529 2022-04-27
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Kadmon Corporation, LLC
Phase 1/2 Terminated
NCT02907918 2021-09-29
PALTAN
Washington University School of Medicine
Phase 2 Terminated
NCT01220128 2021-05-25
INDUCT
GlaxoSmithKline
Phase 2 Terminated
NCT00138125 2020-10-19
Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer
Translational Oncology Research International
Phase 2 Terminated
NCT02774681 2020-04-14
Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis
Northwestern University
Phase 2 Terminated
NCT02726399 2020-01-21
Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00140140 2019-11-26
A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
Celgene
Phase 1/2 Terminated
NCT02318901 2019-10-21
PembroMab
Western Regional Medical Center
Phase 1/2 Terminated
NCT01891357 2019-09-17
Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer
West German Study Group
Phase 2 Terminated
NCT00478140 2019-08-20
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00968968 2019-06-10
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Novartis
Phase 3 Terminated
NCT01185509 2019-01-23
Trastuzumab and Vinorelbine in Advanced Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01912963 2018-12-05
Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT02297230 2018-10-15
Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics
NYU Langone Health
Phase 1/2 Terminated
NCT00954512 2018-08-24
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT00169104 2018-07-20
Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function
Dartmouth-Hitchcock Medical Center
Phase 2/3 Terminated
NCT02379585 2018-04-24
STEFNE
Western Regional Medical Center
Phase 1/2 Terminated
NCT02345772 2018-02-20
Neohttp
Western Regional Medical Center
Phase 1/2 Terminated
NCT01187381 2017-10-20
HERODOT
Hoffmann-La Roche
Terminated
NCT00041470 2017-07-17
Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial
University of Washington
Phase 1/2 Terminated
NCT01774851 2017-06-22
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
Merrimack Pharmaceuticals
Phase 2 Terminated
NCT00088985 2017-06-20
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT02144012 2017-03-07
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer
Hoffmann-La Roche
Phase 3 Terminated
NCT01260194 2016-11-02
A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer
Hoffmann-La Roche
Phase 4 Terminated
NCT01132664 2016-08-17
Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer
Novartis
Phase 1/2 Terminated
NCT00567879 2016-05-09
A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab
Novartis
Phase 1/2 Terminated
NCT00824733 2016-01-14
Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT01388647 2015-08-28
Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer
Vector Oncology
Phase 1/2 Terminated
NCT01290718 2014-12-17
A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.
Hoffmann-La Roche
Phase 2 Terminated
NCT01928615 2014-09-29
LISAH
Hoffmann-La Roche
Phase 2 Terminated
NCT02013765 2014-09-25
A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT01363986 2014-08-11
A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT02005484 2014-08-11
A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression
Hoffmann-La Roche
Phase 2 Terminated
NCT00079326 2014-06-02
Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00118053 2013-11-20
Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated